Actively Recruiting
Pilot Study of Aprepitant Taking to Lower Aldosterone in Adults with Severe Obstructive Sleep Apnea and High Blood Pressure
Led by University Hospital, Rouen · Updated on 2026-05-11
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the role of hyperaldosteronism in patients with obstructive sleep apnea syndrome OSAS and arterial hypertension. This study explores how hyperaldosteronism, which increases arterial stiffness and heart rate variability, may be influenced by nervous system control involving substance P and the NK1 receptor. The study aims to evaluate whether blocking this receptor with aprepitant reduces aldosterone secretion in these patients. Participants will receive either aprepitant or a placebo in a randomized, single-blind setting. The aprepitant group takes oral capsules once daily for four days, starting with 125 mg on day one followed by 80 mg on subsequent days. The placebo group receives matching capsules on the same schedule. The primary focus is to measure the rate of aldosterone secretion immediately after intervention. During the study, participants will undergo assessments to monitor aldosterone levels and related cardiovascular markers. Researchers will track blood pressure and heart function while ensuring adherence to treatment protocols, including replacing certain antihypertensive medications and avoiding licorice products. The study includes follow-up to evaluate the impact of the treatment on aldosterone secretion and related cardiovascular parameters over the study period.
CONDITIONS
Brief Title
EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION
Research Team
A
Antoine-Guy Lopez
N
Nell Marty
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here